Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction

European Journal of Pharmacology

Volumn 308, Issue 2, 1996, Pages 219-225

  Gassen, Michael ^a   Glinka, Yelena ^a   Pinchasi, Bilha ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

apomorphine; ascorbate; free radical; iron; lipid peroxidation; protein carbonyl; thiobarbituric acid

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; PERGOLIDE; SCAVENGER;

ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; DRUG RECEPTOR BINDING; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0030592141     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00291-9     Document Type: Article

References (37)

1. Ben-Shachar, D., P. Riederer and M.B.H. Youdim, 1991, Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease, J. Neurochem. 57, 1609.
2. Braughler, J.M., J.F. Pregenzer, R.L. Chase, L.A. Duncan, E.J. Jacobson and J.M. McCall, 1987, Novel 21-aminosteroids as potent inhibitors of iron-dependant lipid peroxidation, J. Biol. Chem. 262, 10438.
3. Chan, P.H., 1994, Oxygen radicals in focal cerebral ischemia, Brain Pathol. 4, 59.
4. Fagni, L., M. Lafon-Cazal, G. Rondouin, O. Manzoni, M. Lerner-Natoli and J. Bockaert, 1994, The role of free radicals in NMDA-dependent neurotoxicity, Prog. Brain Res. 103, 381.
5. Fahn, S. and G. Cohen, 1992, The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol. 32, 804.
6. Felten, D.L., S.Y. Felten, R.W. Fuller, T.D. Romano, E.B. Smalstig, D.T. Wong and J.A. Clemens, 1992. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats, Neurobiol. Aging 13, 339.
7. Frankel, J.P., A.J. Lees, P.A. Kempster and G.M. Stern, 1990, Subcutaneous apomorphine in the treatment of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 53, 96.
8. Gancher, S.T.. J.G. Nutt and W.R. Woodward, 1995, Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance, Mov. Disord. 10, 37.
9. Garvin, C.E., K.K. Gunter and T.E. Gunter, 1990, Manganese and calcium efflux kinetics in brain mitochondria. Advance to manganese toxicity, Biochem. J. 266, 329.
10. Glinka, Y.Y. K.F. Tipton and M.B.H. Youdim, 1996, The nature of inhibition of respiratory complex I by 6-hydroxydopamine, J. Neurochem. 66, 2004.
11. Hall, E.D., 1993, Cerebral ischaemia, free radicals and antioxidant protection, Biochem. Soc. Trans. 21, 334.
12. Henrich-Noack, P., J.H.N. Prehn and J. Krieglstein, 1995, Neuroprotective effects of TGF-β1, J. Neural Transm. Suppl. 43, 33.
13. Hughes, A.J., R. Webster, M. Bovingdon, A.J. Lees and G.M. Stern, 1991, Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations, Clin. Neuropharmacol. 14, 556.
14. Kornhuber, J., M. Weller, K. Schoppmeyer and P. Riederer, 1994, Adamantine and memantine are NMDA receptor antagonists with neuroprotective properties, J. Neural Transm. Suppl. 43, 91.
15. Lange, K.W., W.D. Rausch, W. Gsell, M. Naumann, E. Oestreicher and P. Riederer, 1994, Neuroprotection by dopamine agonists, J. Neural Transm. Suppl. 43, 183.
16. Lees, A.J., 1993, Dopamine agonists in Parkinson's disease: a look at apomorphine, Fund. Clin. Pharmacol. 7, 121.
17. Levine, R.L., 1983, Oxidative modification of glutamine synthase, J. Biolog. Chem. 258, 11828.
18. Levine, R.L., D. Garland, C.N. Oliver, A. Amici, I. Climent, A.-G. Lenz, A. Bong-Whan, S. Shaltiel and E.R. Stadtman, 1990, Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186, 464.
19. LeWitt, P.A., 1994, Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment, J. Neural Transm. Suppl. 43, 171.
20. Linazasoro, G., 1994, Subcutaneous apomorphine in the treatment of Parkinson's disease, Neurologia 9, 1.
21. Liu, J. and A. Mori, 1993, Monoamine metabolism provides an antioxidant defense in the brain against oxidant-and free radical-induced damage, Arch. Biochem, Biophys. 302, 118.
22. Löschmann, P.A., K.W. Lange, H. Wachtel and L. Turski, 1994, MPTP-induced degeneration: interference with glutamatergic toxicity, J. Neural Transm. Suppl. 43, 133.
23. McCormack, J.G. and R.M. Denton, 1989, Influence of calcium ion on mammalian intramitochondrial dehydrogenases, Methods Enzymol. 174, 95.
24. Morel, L. J. Cillard, G. Lescoat, O. Sergent, N. Pasdeloup, A.Z. Ocaktan, M.A. Abdallah, P. Brissot and P. Gillard, 1992, Antioxidant and free radical scavenger activities of iron chelator pyoverdin and hydroxy4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferroxamine, Free Radic. Biol. Med. 13, 499.
25. Olanow, C.W., 1993, A scientific rationale for protective therapy in Parkinson's disease, J. Neural Transm. Gen. Sect. 91, 161.
26. Przuntek, H., 1994, Clinical aspects of neuroprotection in Parkinson's disease, J. Neural Transm. Suppl. 43, 163.
27. Sam, E.E. and N. Verbeke, 1995, Free radical scavenging properties of apomorphine enanatiomers and dopamine: Possible implication in their mechanism of action in parkinsonism, J. Neural Transm. Park. Dis. Dement. Sect. 10, 115.
28. Sam, E.E., P. Augustijns and N. Verbeke, 1994. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection, J. Chromatogr. B. Biomed. Appl. 658, 311.
29. Singer, T.P., 1974, Determination of the activity of succinate NADH, choline and L-glycerophosphate dehydrogenase, in: Methods of Biochemical Analysis, ed. D. Click (Interscience, New York) p. 123.
30. Sorrenti, V., C. Di Giacomo, M. Renis, A. Russo, C. La Delfa, J.R. Perez-Polo and A. Vanella, 1994, Lipid peroxidation and survival in rats following cerebral post-ischaemic reperfusion: effect of drugs with different molecular mechanisms, Drugs Exp. Clin. Res. 20, 185.
31. Stadtman, E.R., 1993, Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions, Annu. Rev. Biochem. 62, 797.
32. Stibe, C.M.H., A.J. Lees, P.A. Kempster and G.M. Stern, 1988, Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet 403.
33. Takei, M., M. Hirumatsu and A. Mori, 1994, Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro, Neurochem. Res. 19, 1199.
34. Tolbert, N.E., 1974, Isolation of subcellular organelles in isopycnic sucrose gradients. Methods Enzymol. 31, 734.
35. Wenk, G.L., W. Danysz and S.L. Mobley, 1994, Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res. 655, 7.
36. Youdim, M.B.H., P. Riederer and D. Ben-Shachar, 1994, The engima of neuromelanin in Parkinson's disaese substantia nigra, J. Neural Transm. Suppl. 43, 113.
37. Zhao, W., J.S. Richardson, M.J. Mombourquette and J.A. Weil, 1995, An in vitro EPR study of the free-radical scavenging actions of the lazaroid antioxidants U-74500A and U-78517F, Free Radic. Biol. Med. 19, 21.